February 2026 SCRI Release Notes Copied
The following updates were completed between January 21 – February 19, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 25003 | USOR 25003 GU 271 Phase 3 Cohort A Saruparib or Placebo + ADT Q28D – v2.0 10APR2025
USOR 25003 GU 271 Phase 3 Cohort B Saruparib or Placebo + Abiraterone + ADT Q28D – v2.0 10APR2025 |
| 24316 | USOR 24316 CH 04 Phase 1 Pirtobrutinib Q28D 02Oct2024 |
| 24303 | USOR 24303 GYN 150 Phase 3 Arm A AZD8205 Q21D – v1.0 05FEB2025
USOR 24303 GYN 150 Phase 3 Arm B Doxorubicin Q21D – v1.0 05FEB2025 USOR 24303 GYN 150 Phase 3 Arm B Paclitaxel Q28D – v1.0 05FEB2025 |
| 25155 | USOR 25155 GI 429 Phase 2 Pumitamig or Nivolumab + FOLFOX Q14D – 27Oct2025 |
| 24154 | USOR 24154 GI 395 Phase 3 Arm E1 T-DXd + 5-FU Q21D – v2.0 03APR2025
USOR 24154 GI 395 Phase 3 Arm E1 T-DXd + Capecitabine Q21D – v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm E2 Trastuzumab + Cisplatin + 5-FU Q2D – v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm E2 Trastuzumab + Oxaliplatin + Capecitabine Q21D – v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M1 T-DXd + Pembrolizumab + 5-FU Q21D – v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M1 T-DXd + Pembrolizumab + Capecitabine Q21D – v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M2 Pembrolizumab + Trastuzumab + Cisplatin + 5-FU Q2D – v2.0 03APR2025 USOR 24154 GI 395 Phase 3 Arm M2 Pembrolizumab + Trastuzumab + Oxaliplatin + Capecitabine Q21D – v2.0 03APR2025 |
| 25031 | USOR 25031 LUN 615 Phase 3 Durvalumab + Carboplatin + Etoposide Q21D – 07FEB2025
USOR 25031 LUN 615 Phase 3 Durvalumab Q28D – 07FEB2025 USOR 25031 LUN 615 Phase 3 Tarlatamab + Durvalumab + Carboplatin + Etoposide Q21D – 07FEB2025 USOR 25031 LUN 615 Phase 3 Tarlatamab + Durvalumab Q28D – 07FEB2025 |
| 24332 | USOR 24332 GU 269 Phase 2 Arm 1 JSB462 + AAA617 Q42D
USOR 24332 GU 269 Phase 2 Arm 2 JSB462 + AAA617 Q42D USOR 24332 GU 269 Phase 2 Arm 3 AAA617 Q42D USOR 24332 GU 269 Phase 2 JSB462 Q14D (randomization period) |
| 24187 | USOR 24187 GYN 154 Phase 3 Part 2 Arm 1 Sacituzumab Tirumotecan +/- Bevacizumab Q42D – 01APR2025
USOR 24187 GYN 154 Phase 3 Part 2 Arm 2 Bevacizumab Q42D – 01APR2025 |
| 25035 | USOR 25035 LUN 616 Phase 3 Dato-DXd Q21D – v1.0 26FEB2025
USOR 25035 LUN 616 Phase 3 Docetaxel Q21D – v1.0 26FEB2025 |
| 25073 | USOR 25073 GU 283 Phase 3 Part 2 Group A 177Lu-TLX591 + SOC D1,15 (IP only) – v6.0 25FEB2025
USOR 25073 GU 283 Phase 3 Part 2 Group A or B ARPI Q30D – v6.0 25FEB2025 USOR 25073 GU 283 Phase 3 Part 2 Group A or B Docetaxel Q21D – v6.0 25FEB2025 |
| 25099 | USOR 25099 LYM 219 Phase 2 Bridging Therapy (Placeholder) – 24JUN2025
USOR 25099 LYM 219 Phase 2 JNJ-90014496 D1 – 24JUN2025 USOR 25099 LYM 219 Phase 2 Lymphodepletion Fludarabine + Cyclophosphamide D-5,-4,-3 – 24JUN2025 |
| 25090 | USOR 25090 LUN 629 Phase 3 Lurbinectedin Q21D – v2.0 03Sep2025
USOR 25090 LUN 629 Phase 3 Tarlatamab D1,8,15 fb D1,15 Q28D – v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 Topotecan IV Q21D – v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 Topotecan PO Q21D – v2.0 03Sep2025 USOR 25090 LUN 629 Phase 3 ZL-1310 Q21D – v2.0 03Sep2025 |
| RM 1324 MCCR |
RM 1324 Phase 1 CR-001 Q28D – 31Dec2025 |
| 25044 | USOR 25044 GU 278 Phase 3 Abiraterone Q28D – 07MAY2025
USOR 25044 GU 278 Phase 3 Cabazitaxel Q21D – 07MAY2025 USOR 25044 GU 278 Phase 3 Docetaxel Q21D – 07MAY2025 USOR 25044 GU 278 Phase 3 Xaluritamig + Abiraterone Q28D – 07MAY2025 |
| 24268 | USOR 24268 CLL 66 Phase 2 NX-5948 Q28D – 18Nov2025 |
| RM 1306 MCCR |
RM 1306 Phase 1a/1b Part A NRM-823 Q21D – v2.0 02SEP2025 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 25049 | PM v2.0; 15th January 2026 | N/A | N/A | Update drug; instructions |
| 25042 | Version 2.0; 10 June 2025 | N/A | Regimen comments; Admin | Update drug; Instructions, frequency |
| 24196 | Version 4.0; 04 Sept 2025 | N/A | Regimen comments; Premedication | N/A |
| 24179 | Version 4.0; 06 November 2025 | N/A | N/A | Update drug; instructions |
| 24093 | PA v4.0; 10 August 2025 | N/A | Regimen comments; admin, prophylaxis | Update drug; instructions |
| 23252 | Version 4.0; 04 July 2025 | N/A | Regimen comments; Prophylaxis, Observation | Update Drug; instructions |
| 23239 | PA v7.0; 21 July 2025 | N/A | Regimen comments; Admin | Update drug; instructions, name |
| 23236 | PA v3.0; 30 July 2025 | N/A | Regimen comments; admin | Update drug; instructions, premedication |
| 22326 | Version 4.0; 10 July 2025 | N/A | Regimen comments; admin | Update drug; Premedication |
| 22325 | PM v7.0; 13th January 2026 | N/A | N/A | Update drug; instructions |
| 22298 | PM v5.0; 18 December 2025 | N/A | N/A | Update drug; dose, form |
| 22297 | PA v4.0; 22 April 2025 | N/A | Regimen comments; admin | Update drug; premedication |
| 22037 | Version 11.0; 12 August 2025 | N/A | Regimen comments; Admin | Update drug; instructions, premedication |
| 23294 | IP Handling Instructions v5.0; 23rd January 2026 | N/A | N/A | Update drug; instructions |
| 24144 | Version 7.0; 15th October 2025 | N/A | N/A | Update drug; instructions, name. Added Drug |
| 24098 | Version 1.0; 06 August 2025 | N/A | Regimen comments; admin, premedication | Update drug; premedication procurement |
| 25086 | Version 6.0; 16 October 2025 | N/A | Regimen comments; admin, observation | Update drug; instructions, New Arm(s) |
| 25086 | PM v6.0; 18th December 2025 | N/A | N/A | Update drug; instructions |
| 24325 | Adding G-CSF per process updated | N/A | N/A | Added Drug |
| 24139 | PCL; 11 November 2025 | N/A | N/A | Update drug; instructions |
| 24025 | Version 3.0, 06NOV2024 | N/A | N/A | Update drug; instructions |
| 24139 | Version 8.0; 22 Sept 2025 | N/A | Regimen comments; admin | Update drug; instructions, procurement |
| 24144 | Version 7.0, 15 October 2025 | N/A | N/A | New Arm(s) |